Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBAvalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF). The MIST trial (NCT06329401) is expected to enroll 300 progressive PF patients, who will receive either one of….
New prototype therapy may repair IPF lung scarring by …
WEBby Steve Bryson, PhD April 26, 2024. Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports. The study provides pharmacological proof of concept for an upcoming Phase 1 ...
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
WEBRecent Posts. Immune cells separate IPF, fibrotic hypersensitivity pneumonitis September 6, 2024; Tales of 2 women, both named Melissa, on their IPF journeys September 3, 2024; Patient journeys highlighted for this year’s PF Awareness Month August 30, 2024 ‘You can’t have that’: The diet restrictions since my transplant August 27, 2024; Phase 1b trial launched of inhaled nintedanib for ...
Top 10 Pulmonary Fibrosis Stories of 2021
WEBJan 3, 2022 · breathing exercises, Collagen turnover, esopremazole, MDM4, N115, pterostilbene, renin-angiotensin system, Salvianolic acid B, Top 10, TXR-1002, TXR-1007, Tyvaso, vitamin D. Pulmonary Fibrosis News counts down its top 10 most-read stories of 2021, noting what made each relevant for the PF community.
Pulmonary Fibrosis Study Shows Enzyme Can Help Reverse Scarring
WEBby José Lopes, PhD February 19, 2018. An enzyme can start a chain of events that leads to cells involved in tissue scarring reversing their fibrosis-generating activity, British and American researchers have discovered. The study dealt with the enzyme’s effect on myofibroblasts — cells involved in wound healing and inflammatory response.
What Is Pulmonary Fibrosis?
WEBSep 24, 2021 · Pulmonary fibrosis (PF), as its name suggests, is a disease marked by scarring — or fibrosis — of the lungs, leading to shortness of breath. PF is part of a larger group of more than 200 lung conditions collectively known as interstitial lung diseases (ILDs), many of which are known to cause progressive fibrosis.. Types and causes of PF. In most cases, the exact cause of lung scarring is ...
Ifetroban cleared to be tested in IPF patients in Phase 2 clinical ...
WEBJun 2, 2023 · The announcement follows the U.S. Food and Drug Administration (FDA) clearance of the company’s investigational new drug (IND) application — a formal request companies submit to regulatory agencies asking permission to start testing an investigational therapy in human trials.
12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
WEBAug 16, 2019 · The average life expectancy of patients with pulmonary fibrosis is three to five years after diagnosis. However, early detection of the disease is key to slowing progression, and conditions such as chronic obstructive pulmonary disease (COPD) or pulmonary arterial hypertension (PAH) can impact disease prognosis.
NP-120, Potential IPF Treatment, Stabilizes Lung Function in Trial
WEBJul 19, 2022 · Most idiopathic pulmonary fibrosis (IPF) patients treated with NP-120 (ifenprodil) in a 12-week clinical trial saw their lung function improve or stabilize, and most also experienced an easing in coughing, according to top-line data announced by the therapy’s developer, Algernon Pharmaceuticals.